NeuroSense Therapeutics Ltd. (NRSN)
Nasdaq · Healthcare · Biotechnology
$4.03+2.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.6M
- 52-week range
- $3.82 – $26.64
- 52-week change
- −82.89%
- EPS (trailing)
- −$47.10
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Net income
- −$11.1M
- Diluted EPS
- −$0.44
- Free cash flow
- −$7.7M
From the company’s annual report on SEC EDGAR.
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Headquarters: Herzliya, Israel · 17 employees · neurosense-tx.com